US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ホーム
投資
株式
カナダ
TSXV
Encanto Potash Corp (EPO.H) 銘柄情報

Encanto Potash Corp (EPO.H)

0.055

0.00

(0.00%)

終了 7月12日 5:00AM

Encanto Potash Corp (EPO.H) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.055

( - )

買値

0.055

売値

0.06

出来高

1,055

平均取引量 (3 か月)

$ 14,410

財務取引量

-

0.055 日の範囲 0.055

0.00 52 週間の範囲 0.00

時価総額

企業価値

21.729M

前日終値

0.055

始値

0.055

時刻

最終取引時間

VWAP

-

歳入

-

純利益

-1.77M

発行済株式数

19,098,379

浮動株比率 (%)

81.95%

機関投資家保有比率 (%)

15.81%

配当利回り

PER

-0.67

株価売上高倍率 (PSR)

-

1 株当たり利益 (EPS)

-0.1

ベータ

1.66

Encanto Potash Corp. engages in the exploration and development of potash properties in the province of Saskatchewan, Canada. The company owns interests in the Muskowekwan First Nation Potash Mine project covering an area of approximately 61,114 acres located to the north of Regina in southeastern S... Encanto Potash Corp. engages in the exploration and development of potash properties in the province of Saskatchewan, Canada. The company owns interests in the Muskowekwan First Nation Potash Mine project covering an area of approximately 61,114 acres located to the north of Regina in southeastern Saskatchewan. Encanto Potash Corp. is based in Vancouver, Canada. 詳細を表示

セクター

Materials

業界

Chemicals

ウェブサイト

epotash.com

本社

Vancouver, Canada

設立

-

Encanto Potash Corp is listed in the Materials sector of the トロントベンチャー取引所 with ticker EPO.H. The last closing price for Encanto Potash was $0.06. Over the last year, Encanto Potash shares have traded in a share price range of $ 0.00 to $ 0.00.

Encanto Potash currently has 19,098,379 shares in issue. The market capitalisation of Encanto Potash is $1.05 million. Encanto Potash has a price to earnings ratio (PE ratio) of -0.67.

TSX Venture Exchange Stock Maintenance Bulletins

TSX Venture Exchange Stock Maintenance Bulletins Canada NewsWire VANCOUVER, BC, Sept. 27, 2023 VANCOUVER, BC, Sept. 27, 2023 /CNW/ - TSX VENTURE...

L'OCRCVM permet la reprise de la négociation - EPO.H

L'OCRCVM permet la reprise de la négociation - EPO.H Canada NewsWire VANCOUVER, BC, le 9 mars 2022 VANCOUVER, BC, le 9 mars 2022 /CNW/...

IIROC Trading Resumption - EPO.H

IIROC Trading Resumption - EPO.H Canada NewsWire VANCOUVER, BC, March 9, 2022 VANCOUVER, BC, March 9, 2022 /CNW/ - Trading resumes in: Company:...

Suspension de la négociation par l'OCRCVM - EPO.H

Suspension de la négociation par l'OCRCVM - EPO.H Canada NewsWire VANCOUVER, BC, le 8 juill. 2021 VANCOUVER, BC, le 8 juill. 2021 /CNW/...

IIROC Trading Halt - EPO.H

IIROC Trading Halt - EPO.H Canada NewsWire VANCOUVER, BC, July 8, 2021 VANCOUVER, BC, July 8, 2021 /CNW/ - The following issues have been halted...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

EPO.H - Frequently Asked Questions (FAQ)

What is the current Encanto Potash Corp share price?

The current share price of Encanto Potash Corp is $ 0.055

How many Encanto Potash Corp shares are in issue?

Encanto Potash Corp has 19,098,379 shares in issue

What is the market cap of Encanto Potash Corp?

The market capitalisation of Encanto Potash Corp is CAD 1.05M

What is the 1 year trading range for Encanto Potash Corp share price?

Encanto Potash Corp has traded in the range of $ 0.00 to $ 0.00 during the past year

What is the PE ratio of Encanto Potash Corp?

The price to earnings ratio of Encanto Potash Corp is -0.67

What is the registered address of Encanto Potash Corp?

The registered address for Encanto Potash Corp is 595 Burrard Street, Vancouver, British Columbia, V7X 1J1

What is the Encanto Potash Corp website address?

The website address for Encanto Potash Corp is epotash.com

Which industry sector does Encanto Potash Corp operate in?

Encanto Potash Corp operates in the Chemicals sector

Baxers

I'm not sure it matters. Either way they had the confidence around a similar timeframe to pay for a Platinum sponsorship and ensure they had the full 30min presentation slot in front of the audience that mattered.

rheddle

rheddle 8分前

Some key language in those documents that stands out:

'Finally, an injunction would be against the public interest'
'national security crisis surrounding our nation's limited access to rare earth elements'
'an injunction that stopped exploration would also cut off any p

sharkey1

sharkey1 9分前

And so does Kirko.

wadegarret

wadegarret 9分前

Best year 2009 up 580%- This year up 290% so far

That is, in my real portfolio. Sometimes Wadegarret portfolio performs better, and sometime worse, as I do more trading in my real portfolio. Gernerally speaking I play the same stocks, but sometimes I do a lot more trading in my

Nightdaytrader

Nightdaytrader 11分前

They better do it before October elections because if Dems win, nothing will happen and then in January, 2027, I think Maxine Waters will take over House Banking Committee that oversees FDIC.

Baxers

Baxers 13分前

If they had disclosed then the other side would have had a runaway field day on the information and the stock price would be even further in bits and raising capital would be even more difficult that it already is. Entirely unsurprised that (if my idea is correct) they didn't disclose. Caught betwee

Goats'nCrows

Goats'nCrows 13分前

LC, I have been paying attention, and I have been reading your stances. I mean no offense or attack but I can no more believe that you are spending Saturday to selflessly convince shareholders to save themselves/the company than I can believe the "Cofer is under your bed" crowd.

Ar

learningcurve2020

learningcurve2020 14分前

So what’s Advent doing with 85 employees and about $30M in revenues back in 2024? Plus they have the business and Cognate / River to hold their hand. My belief is they already pivoted as you can see by Advent’s website.

Nemesis18

Nemesis18 19分前

I didn't feel that I needed to answer, but
if the MHRA or FDA issues a definitive rejection or demands a completely new Phase III trial, due to the trial's controversial external-control design, NWBO's valuation will face an existential threat.
Without DCVax-L approval, they would b

kenjiroo

kenjiroo 20分前

I hope I can still spin my head at old age !! Cant wait forever 😜

learningcurve2020

learningcurve2020 21分前

If you were at all paying attention my stance has always been to get off your sheepish butts before it’s too late to 1) force new management 2) claw back Advent 3) get the CDMO up and running! Somehow 2 was achieved but sneakily without the revenues, sadly.

Steady_T

Steady_T 21分前

Wouldn't ADVENT be a wholly owned subsidiary?

CryptoRain

CryptoRain 22分前

Yes it does but those holding through the Jan 5 ex date and then sold will most likely get it too. This company is doing things right

kspar1

kspar1 22分前

https://www.patreon.com/posts/163510848

Impressions on The CHMP Blarcamesine Rejection Justification"

Upbeat re-visit of the CHMP conclusion by Bio_Oko. Basically, he observes that Anavex was trying to get those folks to see the goodness in the numbers, hoping they'd i

Lime Time

Lime Time 23分前

Yeah forgot about this one. Bigtime scam in the past. They used to advertise on iHub. Really good share structure. Will check it out. They put it in the time capsule in 2023. Someone gotta open it up some day

boston745

boston745 23分前

Another example where current management, but not current board, kept Sintx undervalued was back in February of 2025. This attempt to keep Sintx undervalued likely had multiple reasons behind it but that list definitely includes keeping Sintx undervalued for the offering in February and likely again

boston745

boston745 24分前

Another example where current management, but not current board, kept Sintx undervalued was back in February of 2025. This attempt to keep Sintx undervalued likely had multiple reasons behind it but that list definitely includes keeping Sintx undervalued for the offering in February and likely again

Jetmek_03052

Jetmek_03052 24分前

As usual, you are wrong.

I never said I was an "expert" on DBMM's financial reports. I said I had forecast DBMM's revenues pretty accurately. And my past posts about them have been proven to be just that.

Where did I say I was an "expert"? Sounds like your opinion a

Steady_T

Steady_T 25分前

$.17 is proof that the drug has not been approved in 923 days.

The jury i.e. MHRA is still out on whether the drug works or not.

Any other conclusion is based on wishful thinking.

Bizreader

Bizreader 25分前

Yep and let's see what happens going forward giving the current state of affairs. Maybe a pendulum or whiplash experience may be next up giving patterns of history.

larrybaz

larrybaz 25分前

Thanks for all the hard work, SSKILLZ. Should be an interesting contest. I'll be interested to see how the indices fare. We will find out if our collective stock-picking ability paints us as contenders or pretenders!

02opida

02opida 25分前

Recent Trades -
Time ET Ex Price Change Volume
15:36:59 Q 0.0071 0.0008 200,000
15:30:40 Q 0.0071 0.0008 13,579
14:49:32 Q 0.00704 0.00074 25,000
14:49:32 Q 0.007 0.0007 25,000
14:49:32 Q 0.00704 0.00074 25,000
14:49:32 Q 0.007 0.0007 25,000
1

randomwalk007

randomwalk007 26分前

The reason it’s taken so long is BIOAQ had to wait until CERN was shut down to close off the parallel universe and enable the completion of the merger. Duh!

radly

Is this going lower or is it time to buy?

Wilmington Capital Manag...

Highland Copper

Hopscotch Groupe

Preferred Medium Term No...

AusNet Services Holdings...

Gold Springs Resource (QB)

YG Entertainment

Vatic Ventures (PK)

Citigroup Global Markets...

Forward Industries

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。